myTomorrows and Rare Disease Research Partner to Streamline Clinical Trial Access for Rare Disease Patients
核心洞察
myTomorrows (搜索) and Rare Disease Research announced a partnership to improve patient identification and referrals into rare disease clinical trials through structured pathways.
The collaboration will initially support RDR (搜索) sites in Georgia, Florida, and North Carolina, using the myTomorrows (搜索) platform to enable structured referrals from community and specialist physicians.
The partnership aims to reduce administrative burden for trial sites while creating smoother experiences for families and referring providers through centralized workflows.
myTomorrows (搜索), a health technology company specializing in connecting patients and physicians to pre-approval treatment options, has partnered with Rare Disease Research (RDR (搜索)), an independent U.S. clinical research site network, to address critical barriers in rare disease clinical trial access. The collaboration, announced on April 16, 2026, focuses on improving patient identification and referral processes for rare disease studies.
Addressing Key Challenges in Rare Disease Trial Access
Patients with rare diseases (搜索) face significant obstacles when seeking appropriate clinical trials. Complex eligibility criteria, rapidly evolving recruitment needs, and limited visibility into active studies create barriers for both clinicians and families attempting to identify relevant opportunities. Referring physicians often lack practical, consistent methods to connect potentially eligible patients to specialized research sites.
The partnership addresses these challenges by implementing the myTomorrows (搜索) platform to help referring physicians and specialist centers identify potentially relevant RDR (搜索) trials and submit structured referrals directly to RDR site teams. The platform supports preliminary matching against study criteria and improves the completeness and consistency of referral information before site-level review.
Streamlined Referral Process
Under the new collaboration, once a potential match is identified, referring providers can submit referrals to the appropriate RDR (搜索) clinical research team through a centralized workflow designed to reduce fragmented communication and improve coordination. RDR investigators and site teams will continue conducting protocol-specific reviews and determining screening suitability and enrollment according to study requirements.
The collaboration also provides support for patients and families seeking information about RDR (搜索) trials. When appropriate, myTomorrows (搜索) patient navigators will help gather relevant medical information, review potential trial options, and support referrals of potentially eligible patients to RDR for site follow-up.
Operational Efficiency and Patient Benefits
By enabling more structured, better-qualified referrals, the partnership aims to help RDR (搜索) teams spend less time managing incomplete or mismatched inbound requests and more time supporting patients who may be suitable for active studies. The initiative seeks to create smoother experiences for families and referring physicians while improving operational efficiency at the site level.
"This partnership strengthens our ability to connect with patients earlier and more effectively through the physicians and specialist centers already involved in their care," said Han C. Phan, MD, CEO of Rare Disease Research. "More structured referrals and clearer eligibility alignment can help our teams focus on the patients most likely to be a fit for a given study, while creating a more efficient and supportive experience for families and referring providers."
Michel van Harten, M.D., CEO of myTomorrows (搜索), emphasized the administrative benefits: "For trial sites, complex recruitment workflows can create unnecessary administrative burden and slow patient access. By supporting RDR (搜索) with structured referrals, preliminary trial matching, and coordinated patient engagement, we aim to help simplify the path from referral to site follow-up."
Geographic Coverage and Future Impact
Initially, the collaboration will support RDR (搜索)'s sites in Georgia, Florida, and North Carolina. The partnership is designed to support more centralized visibility into referred cases, improve coordination across stakeholders, and reduce reliance on fragmented email-based communication.
myTomorrows (搜索) brings significant experience to the partnership, having previously helped more than 17,700 patients and 3,000 physicians across 440+ sites in more than 135 countries. The company's proprietary technology searches clinical trials and Expanded Access Programs using global public registries to connect patients, physicians, trial sites, and biopharma companies.
RDR (搜索) operates as an independent clinical research site network focused exclusively on rare disease studies, with sites in Georgia, North Carolina, Florida, and New Jersey. The organization partners with biopharma sponsors, contract research organizations, physicians, and patient advocacy organizations to expand access to clinical trials and deliver patient-centered study execution for rare and complex conditions.